Clinical Trials Browser

Breast Neoplasms

Gastric Adenocarcinoma

Salivary Gland Neoplasms

Breast Neoplasms

Advanced Breast Cancer

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

Breast Neoplasms

Colorectal Neoplasms

Brain Neoplasms, Breast Neoplasms

Brain Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Neoplasms

Breast Cancer Metastatic

Colorectal Neoplasms

Brain Neoplasms, Breast Neoplasms

Brain Neoplasms, Glioblastoma, Neoplasm Metastasis, Meningeal Carcinomatosis

Carcinoma, Non-Small-Cell Lung

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

Breast Neoplasms

Carcinoma, Non-Small-Cell Lung

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Ovarian Neoplasms, Recurrence

Neoplasm Metastasis, Neoplasms

Stomach Neoplasms

Stomach Neoplasms

Breast Neoplasms

HER2-positive Breast Cancer

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Inflammatory Breast Neoplasms

Neoplasm Metastasis

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Breast Cancer With Brain Metastasis

Breast Neoplasms

Breast Cancer With Brain Metastasis

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Brain Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Meningeal Carcinomatosis

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

HER2-negative Breast Cancer

Esophageal Neoplasms, Stomach Neoplasms, Neoplasm, Residual

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Triple Negative Breast Neoplasms

Clinical Trials

ERADICATE

Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

TRANSCENDER

PONTIAC

Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction

TOP-REAL

Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)

TUXEDO-4

Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases

Trial of Trastuzumab Deruxtecan in Previously Treated HER2

ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis

Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer

HERCULES

CHIMERA

DISCORDANT

ELPIS

Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer

STORM

Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer

TROY

Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers

Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer

Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

ANISE

Scalp Cooling in MBC

ADAPTHER2-IV

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

TRADE DXd

TRUDI

Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid Tumors

ALTER

THUNDER

ARIADNE

THUMB

INOVATE

DEMETHER

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

DEBBRAH

DAISY

SURVIVE HERoes

Heterogeneity of 68Ga-FAPI Uptake As Imaging Biomarker in T-DXd Treatment for Brain Metastasis of HER2 Positive Breast Cancer

ORIENTA

DECIPHER

Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer

HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer

Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer Trial

T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients